Raymond James Financial
HOWL icon

Raymond James Financial’s Werewolf Therapeutics HOWL Stock Holding History

Raymond James Financial’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.5K Buy
+19,778
New +$13.5K ﹤0.01% 5223
2025
Q4 		– Sell
-14,436
Closed -$28.4K – 5242
2025
Q3 		$28.4K Buy
14,436
+1,392
+11% +$1.91K ﹤0.01% 4880
2025
Q2 		$14.2K Buy
+13,044
New +$13.4K ﹤0.01% 5752

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James Financial's HOWL Position: Q1 2026 in Review

Raymond James Financial opened a new position in Werewolf Therapeutics (HOWL) in Q1 2026: 19,778 shares worth $16.5K. The stake represents ﹤0.01% of the portfolio and ranks #5223 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in HOWL as recently as Q3 2025.

Raymond James Financial first reported a position in HOWL in Q2 2025 and has held it in 3 quarters since. The position peaked at $28.4K in Q3 2025. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Raymond James Financial held 19,778 shares of Werewolf Therapeutics worth $16.5K as of Q1 2026.
  • Werewolf Therapeutics was a new Raymond James Financial position in Q1 2026.
  • Werewolf Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5223 holding.
  • Raymond James Financial first reported a position in Werewolf Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Raymond James Financial's Werewolf Therapeutics position peaked at $28.4K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.